Use AI to Detect Lower GI Disorders
With an aging population and increasing provider shortage, clinicians are struggling to keep up with demand for care, while being asked to deliver more with less. Provider organizations broadly struggle to identify and prioritize patients who have, or will have, the greatest need for lower GI care.
AI-Powered Lower GI Detection
Lucem Health Reveal for Lower GI uses your existing data to identify patients who appear to be at a higher risk for lower GI disorders, but who are overdue for standard screening. By leveraging a proven AI algorithm to look far beyond anemia and identify patterns that humans cannot, Reveal for Lower GI helps you detect lower GI disorders earlier, treat them more effectively, and improve both patient outcomes and your bottom line.
Reveal for Lower GI Features
Efficient
Presents a simple list of higher risk patients who should receive priority follow-ups
Intuitive
Excludes predisposing risk factors (such as anemia)
Integrated
Complements and enhances your existing clinical workflows
Secure
Proven data security with HIPAA compliance and SOC 2 certification
How It Works
See how early detection and intervention can improve outcomes and quality of life for patients enabling treatment before a patient’s a condition may become more difficult and expensive to manage.
The Impact of Colorectal Cancer
According to the CDC colorectal cancer is the fourth leading cause of cancer death in the U.S., but it doesn’t have to be. Few preventive interventions are as reliably effective in reducing avoidable death as screening for colorectal cancer.
Many are working to increase screening rates of colorectal cancer (CRC) in the United States with the goal of achieving 80%. However, approximately 32% of age-eligible U.S. adults do not follow the current CRC screening guidelines. CRC can even be prevented if asymptomatic polyps and other early-stage cancers are detected and treated early. Better tools and associated clinical outreach are needed to encourage patient compliance, particularly for patients at highest risk.
Published Research
Reveal for Lower GI has been thoroughly studied and tested in a number of different clinical settings to prove real-world efficacy.
From Partners You Can Trust
Lucem Health partnered with Medial EarlySign to develop the Reveal for Lower GI solution.
About Medial EarlySign
Medial EarlySign’s clinical machine learning software solutions help healthcare stakeholders keep patients healthier longer. Healthcare clients derive actionable and personalized clinical insights from massive amounts of health data leading to potential improvements in quality care, outcomes, diagnostic efficiency, and to accelerate the latest advances in drug research and therapy. EarlySign’s AlgoMarkers and predictive solutions can help clients select enriched subpopulations and more accurately identify and prioritize patients for multiple conditions for interventions to halt or prevent the serious complications from the onset of disease or optimize clinical trials design and recruitment. The company’s purpose-built development environment enables fast, accurate, and explainable models supported by peer-reviewed research published by internationally recognized health organizations and hospitals.
